Proteomic and Metabolomic Changes in Psoriasis Preclinical and Clinical Aspects

Abstract

Skin diseases such as psoriasis (Ps) and psoriatic arthritis (PsA) are immune-mediated inflammatory diseases. Overlap of autoinflammatory and autoimmune conditions hinders diagnoses and identifying personalized patient treatments due to different psoriasis subtypes and the lack of verified biomarkers. Recently, proteomics and metabolomics have been intensively investigated in a broad range of skin diseases with the main purpose of identifying proteins and small molecules involved in the pathogenesis and development of the disease. This review discusses proteomics and metabolomics strategies and their utility in research and clinical practice in psoriasis and psoriasis arthritis. We summarize the studies, from in vivo models conducted on animals through academic research to clinical trials, and highlight their contribution to the discovery of biomarkers and targets for biological drugs.

Investigating causal associations among gut microbiota, metabolites, and psoriatic arthritis: a Mendelian randomization study

“…At present, advanced OMIC technologies have been implemented to investigate the underlying pathophysiological mechanisms of PsA ( Gurke et al, 2022 ). There is a growing body of evidence indicating that changes in the gut microbiota (GM) and metabolic molecules have a substantial impact on the development and progression of PsA ( Olejniczak-Staruch et al, 2021 ; Radulska et al, 2023 ). Specifically, dysbiosis causes the imbalance between the various subtypes of CD4 + T cells that leads to chronic inflammation in the joints, resulting in a range of clinical symptoms such as arthritis, tendonitis, sacroiliitis, and more ( Schatteman et al, 1995 ).…”

Multi-Omics Approach to Improved Diagnosis and Treatment of Atopic Dermatitis and Psoriasis

“…The incidence of IMIDs is growing in industrial societies; environmental changes combined with a genetic background trigger the development of IMIDs [4][5][6]. Recent evidence underpins the presence of shared common pathways among IMIDs [2,6,7], but knowledge of the immune factors that drive these chronic progressive diseases is still incomplete. Treatments of IMIDs are effective in providing clinical benefits to patients, but long-term disease control is still largely unmet [6].…”